Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 907-910

  D'Avolio, Antonio ^a   Simiele, Marco ^a   Calcagno, Andrea ^a   Siccardi, Marco ^b   Larovere, Giovanna ^a   Agati, Silvia ^a   Baietto, Lorena ^a   Cusato, Jessica ^a   Tettoni, Mariacristina ^a   Sciandra, Mauro ^a   Trentini, Laura ^a   Di Perri, Giovanni ^a   Bonora, Stefano ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

HIV antiviral pharmacology; Intracellular concentration; Pharmacokinetics; Plasma concentrations

Indexed keywords

ATAZANAVIR; DARUNAVIR; LOPINAVIR; RITONAVIR; TIPRANAVIR;

ADULT; ARTICLE; BLOOD SAMPLING; CELL COUNT; CELL VOLUME; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSOL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLASMA; RITONAVIR;

EID: 84875263937     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks484     Document Type: Article

References (16)

1. Hogg RS, Heath KV, Yip B et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-4.
2. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
3. Antinori A, Marcotullio S, Ammassari A et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol 2011; 34: 109-46.
4. Bucher HC, Wolbers M, Porter K. 2010 guidelines for antiretroviral treatment of HIV from the International AIDS Society-USA Panel. JAMA 2010; 304: 1897; author reply 1897-8.
5. Hull MW, Montaner JS. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 2011; 43: 375-88.
6. Zhang L, Ramratnam B, Tenner-Racz K et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340: 1605-13.
7. Gupta P, Leroux C, Patterson BK et al. Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral quasi species between blood and semen. J Infect Dis 2000; 182: 79-87.
8. Venturi G, Catucci M, Romano L et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000; 181: 740-5.
9. Khoo SH, Hoggard PG, Williams I et al. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 2002; 46: 3228-35.
10. D'Avolio A, Simiele M, De Francia S et al. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). J Pharm Biomed Anal 2012; 59: 109-16.
11. D'Avolio A, Simiele M, Siccardi M et al. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J Pharm Biomed Anal 2011; 54: 779-88.
12. Simiele M, D'Avolio A, Baietto L et al. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a Coulter Counter to determine intracellular drug concentrations. Antimicrob Agents Chemother 2011; 55: 2976-8.
13. Ford J, Boffito M, Wildfire A et al. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2388-93.
14. Ford J, Cornforth D, Hoggard PG et al. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir Ther 2004; 9: 77-84.
15. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 2004; 54: 982-90.
16. D'Avolio A, Baietto L, Siccardi M et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30: 662-9.